Weight-loss drugs show promise in heart attack recovery, study finds

A team of researchers at Bristol Medical School has discovered that weight-loss drugs commonly prescribed for diabetes may offer an unexpected benefit: they help the heart recover after a heart attack by restoring blood flow to damaged tissue.

The finding centers on a stubborn problem that cardiologists know well. When someone suffers a heart attack, emergency treatment typically involves clearing the main blocked artery to restore circulation. But in nearly half of all cases, the smaller blood vessels within the heart muscle remain constricted even after that primary intervention succeeds. This phenomenon, called "no-reflow," prevents blood from reaching parts of the heart that desperately need it, leading to additional tissue death and complications. Svetlana Mastitskaya, who led the study published in Nature Communications, describes it as a critical gap in current treatment: tiny vessels stay narrowed despite the main artery being cleared.

The drugs in question are GLP-1 receptor agonists—medications that work by mimicking a hormone the body produces naturally to regulate appetite and blood sugar. They've become widely known as weight-loss drugs, but their mechanism goes deeper. The Bristol team found that these drugs improve blood flow by activating potassium channels and relaxing pericytes, the muscle cells that wrap around blood vessels. When pericytes relax, the constricted vessels can open wider, allowing blood to reach areas it couldn't before. The researchers tested this theory in rodents and then verified the mechanism using cultivated human heart cells, building a bridge between animal models and human biology.

What makes this discovery particularly significant is that the cardiovascular benefits appear independent of weight loss itself. The FDA approved semaglutide, a GLP-1 drug marketed as Wegovy, in 2024 specifically to reduce the risk of heart attack, stroke, and other cardiovascular events. In clinical trials, patients taking the medication experienced significantly fewer cardiac events—and these benefits held true whether the patient was only slightly overweight or severely obese. Researchers believe the drugs work through multiple pathways: reducing inflammation, improving blood pressure control, lowering cholesterol and blood fats, and supporting the overall health of blood vessel walls.

Yet the story doesn't end with the drugs themselves. A recent study from Harvard University examined patients with type 2 diabetes taking GLP-1 medication and found that those who also maintained eight specific healthy lifestyle habits—a nutritious diet, regular exercise, not smoking, adequate sleep, minimal alcohol, good stress management, strong social connections, and no opioid use disorder—had a 60 percent lower risk of cardiovascular problems compared to those adhering to one or fewer of these habits. Frank Hu, the study's author, emphasized that even in an era of powerful medications, lifestyle remains central to managing both diabetes and heart disease risk, and can substantially amplify what the drugs alone can achieve.

The implication is clear: weight-loss drugs represent a new tool in cardiac recovery, but they work best as part of a broader approach. The medications can prevent the microscopic traffic jams that block blood flow after a heart attack, but they cannot replace the foundational work of eating well, moving regularly, sleeping soundly, and managing stress. The drugs open the door; the patient's choices determine how far through it they walk.